CLL1-CD33 cCAR is a compound Chimeric Antigen Receptor immunotherapy with two distinct functional CAR molecules expressed on a T-cell, directed against the surface proteins CLL1 and CD33.
CLL1 is associated with leukemia stem cells and disease relapse, while CD33 is expressed on bulky AML disease.
14) Base case 7(C1L1,C4L1, 100,000 C7L1L4,C9L1L3, C10L1) Level 1 mortality 7(C1L1,C4L1, 100,000 C7L1L4,C9L1L3, C10L1) Level 2 mortality 7(ClL1
,C4L1, 100,000 C7L1L4,C9L1L3, C10L1) Level 3 mortality 7(C1L1,C4L1, 100,000 C7L1L4,C9L1L3, C10L1) Level 4 mortality 7(C1L1,C4L1, 100,000 C7L1L4,C9L1L3, C10L1) Two-allele case (Fig.
CLT030 targets C-type-like lectin 1 (CLL1, also known as CLEC12A), a cell surface antigen expressed in nearly all AML cell subtypes, including leukemic stem cells, but not on normal hematopoietic stem cells.
This expression profile differentiates CLL1 from CD33, a common target for targeted AML therapeutics, as it may allow faster hematopoietic recovery in treated patents compared to a CD33-targeting therapeutic.
China successfully generated a cCAR that contains two independent complete units targeting CD33 for a bulky leukemia and CLL1 for leukemic stem cells.
In mouse models generated by cell lines engineered expressing CLL1 or CD33 and AML cell line U937 cells, the cCAR T cells significantly reduced tumor burden and prolonged survival.
CLT030-ADC targets C-type-like lectin 1 (CLL1), a cell surface antigen highly expressed on leukemic stem cells but not on normal hematopoietic stem and progenitor cells.
The company and others have shown that CLL1 is expressed in approximately 90% of all AML patient types, including all French American British classifications, all cytogenetic risk categories, and in patients independent of FLT-3 status.